Do atypical antipsychotic agents cause tardive dyskinesia?

Journal of Psychosocial Nursing and Mental Health Services

Volumn 42, Issue 10, 2004, Pages 14-19

  Bailey, Katharine P ^a  

^a Clinical Affairs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; CLASSIFICATION; DRUG SCREENING; DYSKINESIA; HUMAN; INCIDENCE; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; DRUG EVALUATION; DYSKINESIA, DRUG-INDUCED; HUMANS; INCIDENCE; SCHIZOPHRENIA;

EID: 16544394073     PISSN: 02793695     EISSN: None     Source Type: Journal    
DOI: 10.3928/02793695-20041001-06     Document Type: Review

References (32)

1. Arato, M., O'Connor, R., Meltzer, H.Y., & ZEUS Study Group. (2002). A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: The ziprasidone extended use in schizophrenia (ZEUS) study. International Clinical Psychopharmacology, 17, 207-215.
2. Beasley, C.M., Jr., Tollefson, G., Tran, P., Satterlee, W., Sanger, T., & Hamilton, S. (1996). Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology, 14, 111-123.
3. Bleuler, E. (1950). Dementia praecox, or the group of schizophrenias (J. Zinkin, Trans.). New York: International Universities Press. (Original work published 1911)
4. Brecher, M., Jeste, D., Okamato, A., et al. (1998, December). Low frequency of tardive dyskinesia in elderly patients with dementia exposed to risperidone for up to one year. Paper presented at the 37th annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico.
5. Casey, D.E. (2000). Update on tardive dyskinesia. Journal of Clinical Psychiatry, 61(Suppl. 4), 5-9.
6. Chouinard, G., Gharabawi, G., & Lasser, R. (2003). State of confusion: Measurement, classification, and research regarding drug-induced abnormal movement and posture (DIAMP) disorders [Abstract]. Canadian Journal of Clinical Pharmacology, 10, 131.
7. Correll, C.U., Leucht, S., Kane, J.M. (2004). Lower risk of tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. American Journal of Psychiatry, 161, 414-425.
8. Crane, G.E. (1972). Pseudoparkinsonism and tardive dyskinesia. Archives of Neurology, 27, 426-430.
9. Csernansky, J.G., Mahmoud, R., Brenner, R., & Risperidone-USA-79 Study Group. (2002). A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine, 346, 16-22.
10. Fenton, W.S. (2000). Prevalence of spontaneous dyskinesia in schizophrenia. Journal of Clinical Psychiatry, 61(Suppl. 4), 10-14.
11. Fenton, W.S., Blyler, C.R., Wyatt, R.J., & McGlashan, T.H. (1997). Prevalence of spontaneous dyskinesia in schizophrenic and in schizophrenic and nonschizophrenic psychiatric patients. British Journal of Psychiatry, 171, 265-268.
12. Friedman, J.H. (2004). Historical perspective on movement disorders. Journal of Clinical Psychiatry, 65(Suppl. 9), 3-8.
13. Glazer, W.M. (2000). Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. Journal of Clinical Psychiatry, 61(Suppl. 4), 15-20.
14. Glazer, W.M., Morgenstern, H., Pultz, J.A., et al. (1999, December). Incidence of persistent tardive dyskinesia may be lower with quetiapine treatment than previously reported with typical antipsychotics in patients with psychoses. Paper presented at the 38th annual meeting of the American College of Neuropsychopharmacology, Acapulco, Mexico.
15. Jeste, D.V., Caligiuri, M.P., Paulsen, J.S., Heaton, R.K., Lacro, J.P., Harris, M.J., et al. (1995). Risk of tardive dyskinesia in older patients: A prospective longitudinal study of 266 outpatients. Archives of General Psychiatry, 52, 756-765.
16. Jeste, D.V., Lacro, J.P., Bailey, A., Rockwell, E., Harris, M.J., & Caligiuri, M.P. (1999). Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. Journal of the American Geriatrics Society, 47, 716-719.
17. Kane, J.M., & Smith, J.M. (1982). Tardive dyskinesia: Prevalence and risk factors, 1959 to 1979. Archives of General Psychiatry, 39, 473-481.
18. Kane, J.M., Woerner, M,. Borenstein, M., Wegner, J., & Lieberman, J. (1986). Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacology Bulletin, 22, 254-258.
19. Kane, J.M., Woerner, M., Weinhold, P., Wegner, J., Kinon, B., & Borenstein, M. (1984). Incidence of tardive dyskinesia: Five-year data from a prospective study. Psychopharmacology Bulletin, 20, 387-389.
20. Khot, V., & Wyatt, R.J. (1991). Not all that moves is tardive dyskinesia. American Journal of Psychiatry, 148, 661-666.
21. Kraepelin, E.P. (1971). Dementia praecox and paraphrenia (R.M. Barclay, Trans., G.M. Robertson, Ed.). Huntington, NY: Robert E. Krieger. (Original work published 1919)
22. Lieberman, J.A., Saltz, B.L., Johns, C.A., Pollack, S., Borenstein, M., & Kane, J. (1991). The effects of clozapine on tardive dyskinesia. British Journal of Psychiatry, 158, 503-510.
23. McCreadie, R.G., Padmavati, R., Thara, R., & Srinivasan, T.N. (2002). Spontaneous dyskinesia and parkinsonism in never-medicated, chronically ill patients with schizophrenia: 18-month follow-up. British Journal of Psychiatry, 181, 135-137.
24. McCreadie, R.G., Thara, R., Srinivasan, T.N., & Padmavati, R. (2003). Spontaneous dyskinesia in first-degree relatives of chronically ill, never-treated people with schizophrenia. British Journal of Psychiatry, 183, 45-49.
25. McManus, D.Q., Arvanitis, L.A., & Kowalcyk, B.B. (1999). Quetiapine, a novel antipsychotic: Experience in elderly patients with psychotic disorders. Journal of Clinical Psychiatry, 60, 292-298.
26. Morgenstern, H., & Glazer, W.M. (1993). Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications: Results of the Yale Tardive Dyskinesia Study. Archives of General Psychiatry, 50, 723-733.
27. Psychopharmacology Research Branch, National Institute of Mental Health. (1976). Abnormal involuntary movement scale (AIMS). In N. Guy (Ed.), ECDEU assessment manual for psychopharmacology (Rev. ed., pp. 534-537, U.S. Department of Health, Education, and Welfare Publication No. [ADM] 76-338). Rockville, MD: National Institute of Mental Health.
28. Schooler, N.R. (1991). Maintenance medication for schizophrenia: Strategies for dose reduction. Schizophrenia Bulletin, 17, 311-324.
29. Schooler, N.R., & Kane, J.M. (1982). Research diagnoses for tardive dyskinesia [Letter]. Archives of General Psychiatry, 39, 486-487.
30. Tollefson, G.D., Beasley, C.M., Jr., Tran, P.V., Street, J.S., Krueger, J.A., Tamura, R.N., et al. (1997). Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. American Journal of Psychiatry, 154, 457-465.
31. van Harten, P.N., Hoek, H.W., Matroos, G.E., Koeter, M., & Kahn, R.S. (1998). Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curacao Extrapyramidal Syndromes Study III. American Journal of Psychiatry, 155, 565-567.
32. Woerner, M.G., Kane, J.M., Lieberman, J.A., Alvir, J., Bergmann, K.J., Borenstein, M., et al. (1991). The prevalence of tardive dyskinesia. Journal of Clinical Psychopharmacology, 11, 34-42.